NephroGenex, Biomedical Research Foundation, Karolinska Institute deal

NephroGenex acquired exclusive commercialization rights to the foundation's inhibitors of goodpasture antigen binding protein (GPBP) kinase. High levels of the kinase are associated with inflammatory ...